MAP2K7 and neoplasm: Most pancreatic cancer cells, including MiaPaCa2, have common activating point mutations in KRAS, leading to uncontrolled activation of downstream intracellular signalling pathways, including the RAF/MEK/ERK pathway, contributing to tumour cell proliferation and survival31,38.